Namodenoson is a synthetic, small-molecule A3 adenosine receptor (A3AR) agonist under investigation as a potential therapeutic agent for hepatocellular carcinoma, pancreatic cancer, and metabolic dysfunction-associated… Read more
Namodenoson is a synthetic, small-molecule A3 adenosine receptor (A3AR) agonist under investigation as a potential therapeutic agent for hepatocellular carcinoma, pancreatic cancer, and metabolic dysfunction-associated steatohepatitis. As a highly selective agonist, this purine nucleoside works by modulating Wnt and NF-κB signaling pathways to induce apoptosis in tumor cells and exert anti-inflammatory and anti-fibrotic effects in the liver. To support the rigorous demands of pharmaceutical development, this category provides essential tools for analytical testing and quality control. Laboratories utilize these high-quality reference standards and impurities for impurity profiling and method validation, ensuring precise quantitative measurements during the drug development lifecycle. Additionally, stable isotope labelled compounds are available to serve as internal standards in mass spectrometry-based assays, facilitating accurate pharmacokinetic studies and metabolic analysis of the parent drug and its related derivatives.